United Therapeutics Must Prove Tyvaso Can Stabilize While the Market Waits for Approvals

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

United Therapeutics reports before market open, meaning Day 0 represents the first trading session where the market reacts to results, while Day +1 captures follow-through momentum.

United Therapeutics has exhibited substantial volatility around earnings releases, with an average absolute Day 0 move of 5.78% and Day +1 move of 3.02%. The stock's post-earnings behavior shows a wide range of outcomes, from dramatic moves like the +13.03% surge on Day 0 following the Q4 2025 report to more muted reactions like the +0.06% move after Q2 2026 earnings.

The most recent quarter (Q2 2026) showed relatively subdued initial reaction despite beating estimates, with only a 0.06% Day 0 move followed by a stronger +2.68% Day +1 continuation. This contrasts sharply with earlier quarters: Q1 2026 saw a +4.29% Day 0 pop followed by a -4.62% Day +1 reversal, while Q4 2025's massive Day 0 rally gave back ground with a -5.89% Day +1 decline.

The historical pattern suggests investors should prepare for significant volatility, with Day 0 intraday ranges averaging 8.99% and Day +1 ranges averaging 4.30%. The direction of moves has been inconsistent, with no reliable correlation between beats/misses and price action, indicating that guidance and forward commentary often matter more than the headline numbers.

Part 2.2: Options Market Expected Move

The options market is pricing a 2.97% expected move for the November 20 expiration (17 days out), which is notably more conservative than United's average historical Day 0 move of 5.78% and even below the average Day +1 move of 3.02%. This suggests options traders may be underpricing potential volatility, particularly given the stock's history of dramatic post-earnings swings and the significant uncertainty around the Liquidia settlement's commercial impact.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on United Therapeutics with an average recommendation of 4.25 (between Buy and Strong Buy) and a mean price target of $662.19, implying 10.1% upside from the current price of $601.32. The consensus includes 10 Strong Buy ratings, 2 Moderate Buy ratings, 3 Hold ratings, and 1 Strong Sell rating among 16 analysts covering the stock.

Price target estimates show considerable dispersion, ranging from a high of $850.00 to a low of $368.00, reflecting divergent views on the company's growth trajectory and the potential impact of pipeline catalysts. The wide 131% spread between the high and low targets underscores the uncertainty around key variables like the IPF indication approval and the durability of Tyvaso's competitive position post-Liquidia settlement.

Analyst sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 4.25. This stability suggests the analyst community is maintaining conviction in their bullish thesis despite near-term profitability pressures, likely viewing the Liquidia settlement and upcoming FDA decision on IPF as sufficient catalysts to support current valuations. The consensus appears to reflect confidence that United's legal victory will translate into improved commercial performance, though the lack of upward revisions indicates analysts are taking a wait-and-see approach to the Q3 results.

Part 4: Technical Picture

United Therapeutics enters earnings with strong technical momentum, trading at $601.32 and positioned above all major moving averages. The stock sits above its 5-day ($595.24), 10-day ($589.60), 20-day ($566.41), 50-day ($530.53), 100-day ($531.47), and 200-day ($532.84) moving averages, indicating a well-established uptrend across all timeframes.

The Barchart Technical Opinion currently shows a 40% Buy signal, unchanged from last week's 40% Buy but representing a significant improvement from last month's 8% Sell signal. This shift reflects the stock's strong October rally following the Liquidia settlement announcement.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into earnings
• Medium-term (50% Sell): Moderate sell signal suggests some consolidation or resistance in the intermediate timeframe despite recent strength
• Long-term (50% Buy): Moderate buy signal reflects positive longer-term trend structure

The trend characteristics show Average strength and Average direction, suggesting the current uptrend is neither overextended nor weak, but rather in a sustainable middle ground heading into the earnings event.

The technical setup is broadly supportive heading into earnings, with the stock trading 12.9% above its 200-day moving average and maintaining position above all shorter-term averages. The 100% Short-term Buy signal indicates strong near-term momentum, though the 50% Medium-term Sell reading suggests some caution is warranted at current levels. Key support likely sits at the 20-day moving average around $566, while the stock's ability to hold above the psychological $600 level will be important. The overall configuration suggests the market has already priced in optimism around the Liquidia settlement, making execution on guidance and commentary about 2027 catalysts critical to sustaining the rally post-earnings.